Chenodeoxycholic Acid

Research use only, not for human use.

A potent natural bile acid at stimulating the nuclear bile acid receptor, farnesoid X receptor (FXR).

A potent natural bile acid at stimulating the nuclear bile acid receptor, farnesoid X receptor (FXR); increases plasma concentrations of GLP-1, C-peptide, glucagon, peptide YY, neurotensin, total bile acids, and FGF19 significantly compared with placebo; also activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis.Other Indication Approved(In Vitro):Chenodeoxycholic acid (CDCA) and Deoxycholic acid (DCA) both inhibit 11 beta HSD2 with IC50 values of 22 mM and 38 mM, respectively and causes cortisol-dependent nuclear translocation and increases transcriptionalactivity of mineralocorticoid receptor (MR). Chenodeoxycholic acid is able to stimulate Ishikawa cell growth by inducing a significant increase in Cyclin D1 protein and mRNA expression through the activation of the membrane G protein-coupled receptor (TGR5)-dependent pathway. Chenodeoxycholic acid (CDCA) induces LDL receptor mRNA levels approximately 4 fold and mRNA levels for HMG-CoA reductase and HMG-CoA synthase two fold in a cultured human hepatoblastoma cell line, Hep G2. Chenodeoxycholic acid-induced Isc is inhibited (≥67%) by Bumetanide, BaCl2, and the cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor CFTRinh-172. Chenodeoxycholic acid-stimulated Isc is decreased 43% by the adenylate cyclase inhibitor MDL12330A and Chenodeoxycholic acid increases intracellular cAMP concentration. Chenodeoxycholic acid treatment activates C/EBPβ, as shown by increases in its phosphorylation, nuclear accumulation, and expression in HepG2 cells. Chenodeoxycholic acid enhances luciferase gene transcription from the construct containing -1.65-kb GSTA2 promoter, which contains C/EBP response element (pGL-1651). Chenodeoxycholic acid treatment activates AMP-activated protein kinase (AMPK), which leads to extracellular signal-regulated kinase 1/2 (ERK1/2) activation, as evidenced by the results of experiments using a dominant-negative mutant of AMPKα and chemical inhibitor.

——

——

CDCA

Metabolic Enzyme/Protease

FXR

Bileacidreceptor

Other Indications

Other Disease

474-25-9

392.572

C24H40O4

>98% (HPLC)

DMSO: ≥ 3.6 mg/mL

C[C@@H]([C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)CCC(O)=O

Cholan-24-oic acid, 3,7-dihydroxy-, (3α,5β,7α)-

(-20℃)

With Ice Pack

≥ 2 years